1	Title: SLC27A2 as a molecular marker of impaired epithelium in	
2	chronic rhinosinusitis with nasal polyps	
3		
4	Short title: SLC27A2 as dysfunctional epithelial marker in CRSwNP	
5		
6	Jaewoo Park ¹ , Jung Yeon Jang ² , Jeong Heon Kim ² , Se Eun Yi ² , Yeong Ju Lee ² , Myeong	
7	Sang Yu ² , Yoo-Sam Chung ² , Yong Ju Jang ² , Ji Heui Kim ^{2,3} and Kyuho Kang ^{1,3}	
8		
9	¹ Department of Biological Sciences and Biotechnology, Chungbuk National University,	
10	Cheongju 28644, Republic of Korea	
11	² Department of Otorhinolaryngology – Head and Neck Surgery, Asan Medical Center,	
12	University of Ulsan College of Medicine, Seoul, Republic of Korea	
13		
14	³ Correspondence	
15	Kyuho Kang, Department of Biological Sciences and Biotechnology, Chungbuk National	
16	University, Cheongju 28644, Republic of Korea.	
17	E-mail: <u>kangk@cbnu.ac.kr</u>	
18		
19	Ji Heui Kim, Department of Otorhinolaryngology – Head and Neck Surgery, Asan Medical	
20	Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seou	
21	05505, Republic of Korea.	
22	E-mail: jhkim0217@amc.seoul.kr	
23		
24	Acknowledgements: This work was supported by the National Research Foundation	
25	(NRF), Republic of Korea, grant (NRF-2020R1C1C1013939 and NRF-	
26	2022R1A2C1011187), which is funded by the Ministry of Science and ICT (MSIT) and	
27	grant (2023IL0014) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul,	
28	Korea.	
29		
30	Conflict of interest: The authors declare that they have no relevant conflicts of interest.	

31 ABSTRACT

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex disease characterized by multiple inflammatory endotypes. Although recent progress has been made in endotype-based classification, developing tailored therapeutic strategies for CRSwNP remains challenging. This study aimed to optimize therapeutic outcomes in CRSwNP by identifying potential molecular markers.

Methods: We utilized an integrated approach that combined bulk and single-cell RNA sequencing (scRNA-seq) to delineate the molecular signatures inherent to the cellular components of nasal polyp (NP) tissue. The levels of C11-BODIPY (as a marker of lipid peroxidation) and *SLC27A2*/FATP2 were assessed using quantitative PCR and immunofluorescence (IF) staining. The effects of lipofermata, a FATP2 inhibitor, were examined in air-liquid interface (ALI) cultured epithelial cells derived from CRSwNP patients and healthy controls.

Results: Deconvolution analysis of NP tissue revealed an upregulation of genes 44 associated with lipid metabolism in the NP epithelium. In CRSwNP patients, we observed 45 46 a significant increase in lipid peroxidation and SLC27A2/FATP2 expression in the NP epithelium. A marked expression of genes critical to metabolic pathways involved in lipid 47 peroxidation was identified in SLC27A2-positive epithelial cells. Additionally, FATP2 and 48 lipid peroxidation staining patterns exhibited a positive correlation in their respective % 49 50 Area levels. Elevated SLC27A2 expression was associated with disease pathogenesis and correlated with disease severity. Treatment with lipofermata resulted in decreased 51 mRNA levels of ALOX15, a key mediator of inflammation and lipid peroxidation, and 52 FOXJ1, a marker of abnormal ciliogenesis. 53

54 **Conclusion:** Elevated *SLC27A2* expression in the NP epithelium correlates with the 55 severity of CRSwNP, highlighting its potential as a therapeutic target for managing 56 advanced CRSwNP cases.

57

58 Keywords

59 Chronic rhinosinusitis with nasal polyps (CRSwNP), FATP2 inhibitor, Lipid peroxidation,

60 SLC27A2 expression, Transcriptomics

61 **1. INTRODUCTION**

Chronic rhinosinusitis (CRS) is a prevalent disease affecting up to 11% and 12% of the 62 population in Europe, South Korea, and the United States, respectively, significantly 63 impairing quality of life by presenting symptoms such as nasal congestion, discharge, 64 facial pressure, anosmia, cough, and fatigue¹⁻³ CRS is traditionally classified into two 65 distinct phenotypes: chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic 66 rhinosinusitis without nasal polyps (CRSsNP).² The endotypes of CRSwNP are 67 determined by the type of inflammation present, including eosinophilic CRSwNP 68 (ECRSwNP; type 2), and non-eosinophilic CRSwNP (nECRSwNP; non-type 2).^{3,4} Type 2 69 CRSwNP is predominant in Western populations, accounting for 80% of cases, while in 70 Asian countries like Korea, Japan, and China, types 1 and 3 are more prevalent, 71 constituting 20–60% of CRSwNP cases.⁴⁻⁷ Recent evidence has elucidated the complex 72 interplay between various inflammatory pathways and tissue remodeling factors, 73 delineating their relevance to the endotypes of CRSwNP.⁸ This growing understanding 74 underscores the importance of a personalized, endotype-targeted approach to the 75 management of CRSwNP.^{3,9} Despite these advances, however, the selection of an 76 77 optimal therapeutic strategy for CRSwNP remains fraught with challenges, particularly 78 due to the paucity of molecular biomarkers that adequately reflect the clinical characteristics of the various CRSwNP types. Moreover, the existence of cases with 79 80 mixed or indistinct endotype-specific features exacerbates the intricacy of treatment decision-making.^{7,9-13} Consequently, CRSwNP remains a significant clinical conundrum 81 in the guest for effective, customized therapeutic interventions. 82

Recent advances in genomic profiling have shed light on the pathogenesis of CRSwNP. 83 providing potential solutions to the challenges faced by affected individuals. Whole-84 85 transcriptome sequencing has revealed gene signatures linked to inflammation and abnormal host defense mechanisms, as well as distinct transcriptomic differences 86 between ECRSwNP and nECRSwNP.¹⁴⁻¹⁶ Single-cell transcriptome profiling has further 87 enriched our understanding by revealing the complex cellular landscape within NP tissue, 88 89 identifying subpopulations of immune and epithelial cells that contribute to type 2 immunity through the expression of pro-inflammatory mediators.^{14,17-22} Imbalances in 90 91 cellular populations, such as basal cell hyperplasia and the loss of ciliated/secretory cells,

92 have also been documented.^{17,21}

Recent focus has turned to the role of lipid and fatty acid metabolic dysregulation in the 93 pathogenesis of CRSwNP.¹⁹⁻²² ALOX15, a lipid mediator implicated in inflammation, has 94 been observed in select subpopulations of macrophages and dendritic cells. Additionally, 95 discernible expression of lipid transport-related genes-PLTP, APOE, ABCA1, and 96 *LRP1*—has been identified within specific subunits of macrophages.²¹ Dysregulated fatty 97 acid metabolism has been observed in nasal polyp-derived eosinophils.²³ Similarly, T 98 helper 2 cells exhibit an enrichment of genes associated with lipid metabolism.²⁰ 99 Imbalances in lipid metabolism can also induce epithelial dysfunction. In tuft cells within 100 the NP epithelium, genes related to the arachidonic acid metabolism pathway, including 101 PTGS1 and ALOX5, have been found to be uniquely enriched.¹⁹ Despite its pro-102 inflammatory effects, ALOX15, a marker of lipid peroxidation, has been previously 103 reported to exhibit robust expression in the NP epithelium.²⁴⁻³¹ Recent findings have 104 highlighted the presence of genes associated with lipid peroxidation in the NP 105 epithelium.³²⁻³⁴ Despite these pivotal studies, our understanding of lipid metabolism in 106 107 epithelial dysfunction remains incomplete, necessitating further research that encompasses all endotypes. 108

109 In this study, we aimed to identify molecular markers associated with aberrant epithelial activity that may serve as potential prognostic and therapeutic targets for patients with 110 111 CRSwNP. We analyzed the cellular composition of NP tissues through deconvolution analysis of bulk and single-cell RNA-seg datasets. Our results demonstrated an increase 112 in the expression of genes related to lipid metabolic processes in the epithelial cells of 113 NPs. We found that fatty acid transporter protein 2 (FATP2), a long-chain fatty acid 114 transporter encoded by the solute carrier family 27-member 2 (SLC27A2) gene, was 115 116 significantly upregulated in NP epithelium compared to healthy control epithelium. Patients with high expression of SLC27A2 exhibited increased mucociliary dysfunction-117 related transcriptional signature genes and severity scores. Inhibition of SLC27A2 118 resulted in decreased expression of epithelial dysfunction-related genes. Our findings 119 120 suggest that SLC27A2 may be a novel prognostic and therapeutic target gene for patients with severe CRSwNP. 121

122 **2. METHODS**

123 2.1 Patient recruitment

We enrolled adult Korean participants with chronic rhinosinusitis with nasal polyps (CRSwNPs) and healthy controls from the Department of Otorhinolaryngology – Head and Neck Surgery at Asan Medical Center (AMC) between July 2019 and April 2022. Written informed consent was obtained from all subjects before the study's commencement, conducted in accordance with the Declaration of Helsinki. This study received approval from the Asan Medical Center Institutional Review Board (IRB No. 2019-0619).

For patients with CRSwNPs, nasal polyp (NP) tissues were collected during functional 131 endoscopic sinus surgery, and diagnoses followed the criteria outlined in the 2020 132 133 European Position Paper on Rhinosinusitis and Nasal Polyps guidelines, which included assessing symptoms, nasal endoscopy findings, and computed tomography (CT) 134 imaging.² Exclusion criteria included patients: 1) below 18 years; 2) with a history of 135 unilateral CRS, antrochoanal polyps, fungal sinusitis, allergic fungal sinusitis, aspirin-136 137 exacerbated respiratory disease, cystic fibrosis, or primary ciliary dyskinesia; 3) who are pregnant or immunocompromised; 4) administered decongestants, antibiotics, and 138 139 systemic/topical corticosteroids over four weeks preceding surgery; and 5) with a history of acute respiratory infection within four weeks prior to surgery. 140

Histopathological examination was performed to rule out fungal sinusitis, allergic fungal
 sinusitis, cystic fibrosis, or primary ciliary dyskinesia. We also inquired about their history
 of acute upper and lower respiratory tract reactions to aspirin or nonsteroidal anti inflammatory drugs to identify aspirin-exacerbated respiratory disease. Additionally, we
 conducted various assessments, including the Sinonasal Outcome Test (SNOT-22),
 Lund-Mackay CT scores, Lund-Kennedy endoscopic score, nasal polyp score, and polyp
 grading according to the Davos classification.^{2,35,36}

Control tissue samples were obtained from the middle turbinate (MT) mucosa of patients above 18 years old undergoing septoplasty for nasal obstruction without sinusitis on CT or transsphenoidal approach surgery for non-functioning pituitary tumors without adjacent structure invasion on MRI and sinusitis on CT scan. These control subjects had no history of asthma, upper respiratory infection, or administration of systemic, topical

153 corticosteroids, or antibiotic medications within four weeks before surgery. We determined

154 atopic status by detecting specific IgE antibodies to common inhalant allergens using

155 ImmunoCAP[™] tests (Phadia, Uppsala, Sweden), and asthma was diagnosed based on

medical history and pulmonary function tests, including spirometry and challenge tests.

157

158 2.2 Utilization of publicly available data

In this study, we employed various publicly available datasets and databases as follows:
 Bulk RNA-seq datasets from Peng et al.¹⁶ and Nakayama, T., et al.¹⁴, single-cell RNA-seq
 datasets from Wang et al.²¹ and Ordovas-Montanes et al.¹⁷, and ATAC-seq data from
 Ordovas-Montanes et al.¹⁷

163

164 2.3 Bulk RNA-seq data analysis

For the analysis of bulk RNA-seq data (GSE136825; GSE179269), we mapped the reads 165 to the hg38 genome using STAR version 2.7.1a with default parameters.³⁷ Subsequently. 166 we converted the aligned reads into tag directories using HOMER version 4.11.1.³⁸ 167 168 Quantification of each file was performed utilizing the "analyzeRepeats" script in HOMER. We normalized gene expression levels in each sample by calculating fragments per 169 170 kilobase of transcript per million mapped reads (FPKM). Differential expression genes (DEGs) were identified through DESeq2 analysis based on raw read counts.³⁹ The 171 172 "getDifferentialExpression" command in HOMER was applied with criteria for significance defined as an adjusted p-value of < 0.05, more than a two-fold difference in expression 173 levels, and an average FPKM > 2. Principal component analysis (PCA) distinctly classified 174 the samples into Healthy and CRSwNP clusters. One Healthy sample, aligning more with 175 176 the CRSwNP cohort, was recognized, and henceforth omitted from further assessments 177 (GSE179269, Figure S2B).

178

179 2.4 Single-cell RNA-seq analysis

180 2.4.1 Surgical biopsy of nasal polyp tissues

To profile the cellular ecosystem of nasal polyp (NP) tissues, we analyzed publicly available single-cell RNA-seq data (accession number HRA000772).²¹ To ensure compatibility with the publicly available bulk RNA-seq dataset (GSE136825) and to

maintain uniformity in disease states and tissue locations, we utilized data from 11
 samples obtained from surgical biopsies of nasal polyp tissues. These samples
 encompassed 5 non-ECRSwNP and 6 ECRSwNP patients.

For our analysis, we included only cells in which mitochondrial RNA accounted for less 187 than 15% of the total RNA content. We performed data integration and anchoring using 188 the top 10,000 highly variable features identified through the variance-stabilizing 189 transformation method. Subsequently, we conducted uniform manifold approximation and 190 projection (UMAP) analysis and constructed a nearest neighbor graph using the 191 'FindNeighbors' function. To identify cell clusters, we employed the 'FindClusters' function 192 with a resolution parameter set to 0.5. Differential expression analysis was carried out 193 using the 'FindMarkers' and 'FindAllMarkers' functions. Additionally, we assessed the 194 195 expression levels of genes associated with lipid metabolism across various cell types using the 'AddModuleScore' function, which calculated module scores based on genes 196 197 related to the GO:0006629 lipid metabolic process.

198

199 **2.4.2 Nasal scrapings**

To identify cell populations expressing elevated levels of SLC27A2, we utilized previously 200 published single-cell RNA-seq data (Ordovas-Montanes et al.).¹⁷ These data included 201 7,886 cells from the ethmoid sinus of 2 patients with chronic rhinosinusitis with nasal 202 203 polyps (CRSwNP-NP), 2,031 cells from the inferior turbinate of 4 patients with CRSwNP (CRSwNP-IT), and 6,498 cells from the inferior turbinate of 3 healthy controls (Healthy-204 IT). We included only those cells in which mitochondrial RNA accounted for less than 20% 205 of the total RNA content. Data integration and anchoring were performed using the top 206 3,500 highly variable features determined by the variance-stabilizing transformation 207 208 method. Subsequently, we conducted uniform manifold approximation and projection (UMAP) analysis and constructed a nearest neighbor graph using the 'FindNeighbors' 209 function. Cluster identification was achieved using the 'FindClusters' function with a 210 resolution parameter set to 0.5. Differentially expressed genes (DEGs) were identified 211 212 using the 'FindMarkers' and 'FindAllMarkers' functions. Principal component analysis and clustering were conducted using Seurat version 4.3.0.1 in R version 4.3.0. 213

214

215 **2.5 Gene ontology analysis**

To identify enriched Gene Ontology (GO) terms among the Differentially Expressed Genes (DEGs), we employed Metascape. ⁴⁰

218

219 2.6 Module GSVA scores

For the assessment of variation in predefined gene sets across samples within our microarray expression datasets, we utilized Gene Set Variation Analysis (GSVA), specifically version 1.48.2, an open-source software available through R/Bioconductor.⁴¹ GSVA provides a non-parametric and unsupervised method for this purpose. The GSVA scores for each sample were calculated using the FPKM gene expression matrix of the selected gene set, and this computation was carried out using the GSVA package in R version 4.3.0.

227

228 2.7 Immunofluorescence

The samples (refer to Table 1) were fixed in 4% paraformaldehyde in phosphate-buffered 229 230 saline (PBS) and subsequently embedded in paraffin using standard procedures. Sections of the specimens, each 4-µm in thickness, were subjected to heat-induced 231 antigen retrieval by boiling in 10 mM citrate buffer (pH 6.0) and allowed to cool to room 232 temperature for 20 minutes. The specimens were then incubated overnight at 4°C with 233 234 anti-FATP2 (14048-1-AP, Proteintech, IL, USA; 1:100) antibodies. Afterward, the specimens were incubated with goat anti-rabbit Alexa Fluor 488 (A11008, Invitrogen, OR, 235 USA; 1:200) and BODIPY[™] 581/591 C11 (D3861, Invitrogen, OR, USA; 10 µM) for 2 236 hours at room temperature. Finally, the sections were counterstained with DAPI (D1306, 237 Invitrogen, OR, USA; 1:1000) and examined using a confocal laser microscope (LSM 900, 238 Carl Zeiss, Germany). Image analysis and quantification were performed using ImageJ 239 version 1.53k. 240

241

242 2.8 Oil Red O (ORO) staining

To assess lipid droplets in the tissue, we employed Oil Red O (ORO) staining. Fixed frozen tissue samples (see Table 1) were rinsed with 60% isopropanol for 2 minutes, followed by staining with a freshly prepared ORO working solution (Sigma-Aldrich,

Catalogue #O1391) for 15 minutes. After staining, the sections were rinsed three times with 60% isopropanol (1 minute each) and twice with distilled water. Subsequently, sections were counterstained with 30% modified Mayer's hematoxylin for 30 seconds, rinsed with tap water and two changes of distilled water, and finally, mounted in aqueous mounting media (Aquatex®, Sigma-Aldrich).

251

252 2.9 Quantitative real-time PCR

Total RNA was extracted from whole-tissue and epithelial cells of CRSwNPs and healthy 253 controls (see Table 1) using the RNeasy Mini kit (QIAGEN). Reverse transcription was 254 carried out using 500 ng of total RNA with the RevertAid First Strand cDNA Synthesis kit 255 (Thermo Fisher Scientific). Real-time quantitative PCR (gPCR) was performed with 256 TOPreal gPCR 2X PreMIX (SYBR Green with low ROX; No. RT500M; Enzynomics Co. 257 Ltd., Daejeon, Korea). The qPCR conditions included an initial cycle at 95°C for 10 258 259 minutes, followed by 50 cycles of 10 seconds at 95°C for denaturation, 15 seconds at 60°C for annealing, and 20 seconds at 72°C for extension. A melting program was 260 261 executed at 72–95°C with a heating rate of 1°C/45 seconds. The Rotor-Gene Q v. 2.3.1 (Qiagen, Hilden, Germany) was utilized to capture and analyze spectral data. 262

263

264 **2.10 ATAC-seq analysis**

265 For ATAC-seq analysis, sequenced reads were aligned to the human genome reference (GRCh38/hg38 assembly) using Bowtie2 version 2.3.4.1 with default parameters, and 266 clonal reads were excluded from further analysis.⁴² A minimum of 10 million uniquely 267 mapped reads was obtained for each condition. To identify peaks of ATAC-seg enrichment 268 over the background, we utilized the 'makeTagDirectory' followed by the 'findPeaks' 269 command from HOMER version 4.11.1.³⁸ A false discovery rate (FDR) threshold of 0.001 270 was applied to all datasets. The total number of mapped reads in each sample was 271 normalized to 10 million mapped reads. To visualize the normalized tag density of genes, 272 273 we used the Integrative Genomics Viewer.

274

275 2.11 Air-liquid interface (ALI) culture

276 Primary human nasal epithelial cells (HNECs) were isolated from either polyp or control

tissues (see Table 1). Passage-2 HNECs (1.5 × 105 cells/well) were seeded in 0.25 mL 277 of culture medium on Transwell clear culture inserts (12 mm, with a 0.4 µm pore size: 278 Costar; Corning Inc., Corning, NY). Initially, cells were cultured in a 1:1 mixture of basal 279 epithelial growth medium and Dulbecco's modified Eagle's medium containing previously 280 described supplements in a submerged state for the first 7-9 days. Upon reaching 281 confluence, the apical medium was removed to establish an ALI, and thereafter, the 282 medium was replenished only in the basal compartment. RNA was extracted from HNECs 283 on day 14 following ALI establishment.^{43,44} 284

285

286 **2.12 In vitro lipofermata treatment**

At day 14 of ALI culture, HNECs were exposed to either dimethyl sulfoxide (DMSO; SIGMA, 276855-100ML) or 2 μ M lipofermata (MedChemExpress, HY-116788), a *SLC27A2*/FATP2 inhibitor, in the apical compartment for 24 hours. RNA was subsequently extracted from HNECs.

291

292 2.13 Statistical analysis

Unless otherwise specified, statistical analyses were performed using GraphPad Prism 293 294 version 9 (GraphPad Software, La Jolla, CA, USA). Data are presented as mean ± standard error (SEM), unless otherwise stated in each figure legend. When applicable, 295 296 two-tailed unpaired t-tests, paired t-tests, ordinary one-way ANOVA, and Wilcoxon signed-rank tests were employed. In all statistical analyses, similar expected variances 297 were assumed between compared groups, and significance was accepted at the 95% 298 confidence level (*P < 0.05, **P < 0.01, ***P < 0.001 for two-tailed unpaired t-tests, paired 299 300 t-tests, and ordinary one-way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001 for Wilcoxon 301 signed-rank tests).

302 3. RESULTS

303 **3.1 Dissecting the nasal polyp transcriptome reveals altered lipid metabolism**

To unveil unique molecular signatures within distinct cell types of NP tissues from 304 CRSwNP patients, we employed a comprehensive transcriptomic approach, utilizing both 305 bulk RNA-seq and scRNA-seq datasets. To enhance statistical robustness, we 306 incorporated a publicly available bulk RNA-seq dataset (GSE136825; 28 Healthy, 42 307 CRSwNP).¹⁶ Additionally, we adopted a quality-assured public scRNA-seq dataset 308 (HRA000772; 11 CRSwNP)²¹ to capture cell-type-specific molecular nuances (Figure 1A). 309 Comparative analysis of the GSE136825 dataset revealed 971 differentially expressed 310 genes (DEGs) between the 28 healthy and 42 CRSwNP samples. Among these DEGs, 311 552 were upregulated, and 419 were downregulated in CRSwNP (Figure S1A). 312 313 Subsequent GO analysis shed light on potential molecular pathways and biological implications of these DEGs. Upregulated genes in CRSwNP were associated with GO 314 315 terms such as 'inflammatory response,' 'innate immune response,' 'cellular response to lipid,' and 'superoxide metabolic process,' while downregulated genes were linked to 316 317 'circulatory system process,' 'response to hormone,' and 'salivary secretion' (Figure S1B). Using uniform manifold approximation and projection (UMAP), we identified eight distinct 318 319 cell clusters encompassing 72,032 cells in the HRA000772 dataset. These clusters comprised epithelial cells, NK/T cells, B cells, myeloid cells, fibroblasts, endothelial cells, 320 321 vascular smooth muscle cells (VSMCs), and cycling cells (Figure S1C). Cluster-specific marker genes were employed to delineate these cell types (Figure S1D). 322

Subsequent integrated transcriptome analysis highlighted genes predominantly 323 expressed in each cell type, with a particular focus on those upregulated in CRSwNP 324 patients. These included 45 genes in epithelial cells, 15 in NK/T cells, 7 in B cells, 86 in 325 326 myeloid cells, 23 in fibroblasts, 5 in endothelial cells, 6 in VSMCs, and 19 in cycling cells (Figure 1B, left). A subsequent GO analysis unveiled specific functional themes for these 327 genes, elucidating characteristic GO terms for each cell type, such as 'interleukin-4 and 328 interleukin-13 signaling,' 'long-chain fatty acid metabolic process,' and 'lipid modification' 329 330 for epithelial cells, and 'signaling by ROBO receptors' for NK/T cells, among others (Figure 1B, right). Most of these GO terms aligned with established associations for each cell type 331 332 in NP tissues. However, we gave priority to those GO terms with roles yet to be fully defined. Notably, lipid metabolism-linked GO terms featured prominently in the GO analysis of both whole tissues and specific cell types, especially epithelial and myeloid cells (Figure 1B). While previous studies have highlighted lipid metabolic processes in dendritic cells, macrophages, and Th2 cells^{20,21}, their role in the NP epithelium remains an active area of investigation.

In our effort to comprehend the complex cellular milieu of nasal polyps, we first 338 addressed potential analytical biases. Our primary objective was to identify genes 339 340 associated with lipid metabolic pathways that exhibited elevated expression in CRSwNP patients. Through meticulous transcriptome analysis at the tissue level, we identified a 341 set of 38 genes with increased expression in nasal polyp samples (refer to Figure S1E). 342 Interestingly, pivotal genes such as ALOX5, ALOX5AP, AOAH, APOE, PLA2G7, and 343 344 TREM2 demonstrated marked upregulation in CRSwNP subjects compared to their healthy counterparts (Figure 1C). These genes were intricately linked to molecular 345 processes and biological activities, particularly those related to inflammatory responses, 346 arachidonic acid and eicosanoid metabolism, and lipid oxidation processes (Figure 1D). 347 348 A deeper dive into the module scores of these 38 genes associated with lipid metabolic

pathways revealed pronounced scores, primarily in myeloid, epithelial, and NK/T cells. Notably, epithelial cells exhibited an elevated module score, surpassed only by myeloid cells (Figures 1E and 1F). Our findings shed light on perturbed lipid metabolism in nasal polyp tissue, suggesting that these upregulated genes may be intricately involved in epithelial anomalies and heightened inflammatory events.

354

355 3.2 Augmented lipid peroxidation in nasal polyp epithelium of CRSwNP patients

To explore the potential association between lipid metabolic perturbations and atypical 356 357 NP epithelium in CRSwNP patients, we correlated genes associated with lipid metabolic processes (38 genes) with those expressed in epithelial cells (45 genes). This alignment 358 yielded 6 pertinent genes (Figure 2A). There was a marked difference in the mRNA 359 expression levels of ALOX15, GSTP1, IMPA2, SAA1, SGPP2, and SLC27A2 between 360 361 the healthy and CRSwNP groups (Figure 2B). Furthermore, these genes exhibited robust expression in epithelial cell (Figure 2C and S2A). To reinforce our findings' statistical 362 363 robustness, we incorporated an external public bulk RNA-seq dataset (GSE179269; 7

Healthy, 17 CRSwNP; Figure S2B).¹⁴ In our exploration, CRSwNP patients had 1,290 upregulated genes and 580 downregulated genes. Significantly, of our identified 6 genes, *ALOX15, IMPA2, SGPP2*, and *SLC27A2* were conspicuously elevated in CRSwNP (Figure S2C and S2D). This skewed gene expression hints at disturbances in lipid metabolic processes, possibly pointing to lipid peroxidation and accumulation anomalies.^{26,31,45-47}

Extending our preliminary assessments, we examined lipid accumulation and lipid peroxidation in NP tissues of both healthy controls and CRSwNP patients using Oil Red O (ORO) staining and C11-BODIPY (Figure S2E and Figure 2D). As illustrated in Figure 1D, CRSwNP patients exhibited a pronounced increase in lipid peroxidation relative to the healthy group (Figure 2D and 2E). Our data underscores the likelihood of upregulated genes involved in lipid metabolic dysfunctions in the NP epithelium, which might amplify epithelial irregularities, partially instigated by intensified lipid peroxidation.

377

378 **3.3 Enhanced SLC27A2/FATP2 expression in nasal polyp epithelium**

379 Fatty acid transporters play a critical role in lipid metabolism regulation. Disruption in their expression can significantly affect lipid homeostasis, possibly leading to various cellular 380 abnormalities and diseases.⁴⁸⁻⁵¹ Among the identified candidate genes, SLC27A2 381 encodes for FATP2, a fatty acid transporter. Beyond SLC27A2, we assessed mRNA levels 382 383 of other related genes including the solute carrier 27A (SLC27A) gene family, fatty acid binding proteins (FABPs), and CD36, contrasting their expressions between healthy 384 individuals and CRSwNP patients. Notably, of the 16 genes examined, only SLC27A2 385 exhibited a pronounced elevation in expression in CRSwNP (Figure 2B, 3A, S3A, and 386 S3B). RT-qPCR validation further confirmed the marked difference in SLC27A2 mRNA 387 388 expression levels (Figure 3B). We subsequently investigated whether the alterations in SLC27A2 expression were evident in nasal scrapings as well as in whole tissues.¹⁷ Cells 389 expressing SLC27A2 were notably present in epithelial cell clusters derived from 390 CRSwNP nasal polyps (Figure 3C and 3D). In alignment with this, FATP2 levels were 391 392 notably elevated in the NP epithelium of CRSwNP patients when compared to healthy controls (Figure 3E and 3F). 393

394 Persistent chronic inflammatory stimuli can result in dynamic shifts in chromatin

accessibility across all cellular types, inclusive of epithelial cells.^{17,52-55} Consequently, 395 utilizing Omni-ATAC-seq data,¹⁷ we aimed to identify variations in the *cis*-regulatory 396 components of genes implicated in lipid metabolic pathways, notably SLC27A2, within 397 epithelial cells from nasal polyps. We observed increased chromatin accessibility in 398 promoters and introns of genes linked to lipid metabolic processes (Figures 3G and S3C). 399 Yet, However, these alterations exhibited no discernible differences among the endotypes 400 of CRSwNP. A parallel analysis failed to discern notable differences in mRNA and protein 401 expressions between ECRSwNP and nECRSwNP (Figures S3D, S3E, and S3F). Lipid 402 peroxidation levels appeared consistent across both groups (Figures S3E and S3G). This 403 observation was substantiated further by an external scRNA-seq dataset (HRA000772)²¹ 404 incorporated in our research (Figures S3H, S3I, and S3J). Collectively, our findings 405 406 indicate an elevated expression of SLC27A2 in the epithelial cells of CRSwNP patients, irrespective of the endotype, possibly suggesting an epigenetic memory imprint. 407

408

3.4 Transcriptomic signatures and elevated lipid peroxidation in *SLC27A2*-positive nasal polyp epithelial cells

To elucidate the distinct molecular signature of *SLC27A2*-positive (*SLC27A2*+) cells in the NP epithelium, we employed the scRNA-seq dataset²¹ used for integrated transcriptome analysis (Figure 1). We isolated the epithelial cell cluster, subsequently dividing it into seven subtypes (Figure 4A). Each cluster-specific gene list identified the cell types of these subtypes (Figure S4A).

Using a demarcation of 0 for SLC27A2 expression, we classified epithelial cells into 416 SLC27A2-negative (SLC27A2-) and those with an expression above 0 as SLC27A2+ 417 (Figure 4B). Notably, the SLC27A2+ cells constituted 30.18% of the NP epithelium, with 418 419 a predominance in the Goblet cell, Basal cell, Ciliated cell, and Secretory cell subtypes (Figure S4B). The distribution of SLC27A2+ cells showed a marked presence in Goblet 420 cell (43.10%) and Ciliated cell (13.76%) compared to SLC27A2- cells (Goblet cell, 19.24%; 421 Ciliated cell, 5.06%) (Figure S4C). Among the epithelial subtypes, the Ciliated cell 422 423 exhibited the highest SLC27A2 expression (Figure 4C). Distinct gene expression patterns emerged between the two groups. Genes ALOX15, 424

425 NOS2, CST1, and DUOX1 consistently showed increased expression in SLC27A2+ cells,

while *RPS27A, NFIB, IL33, KRT5,* and *TP63* were more expressed in *SLC27A2*- cells
(Figure 4D). Gene Ontology (GO) analysis revealed unique transcriptomic features: the *SLC27A2*+ group showed increased genes linked to ciliopathies, MHC protein complex
assembly, fatty acid metabolism, and oxidative phosphorylation, whereas the *SLC27A2*group was enriched in genes related to cytokine signaling and immune response
activation (Figure 4E).

In the cohort expressing SLC27A2, an elevated transcriptional response was observed, 432 notably for genes involved in reactive oxygen species (ROS) metabolism and lipid 433 oxidation upregulation (Figure S4D). Key enzymes like ACSL4, LPCAT3, ALOX15, and 434 POR, pivotal for lipid peroxidation initiation, in conjunction with FATP2, showed marked 435 expression disparities (Figure 4F).^{26-29,31,56} Immunofluorescence (IF) analysis revealed a 436 437 concurrent localization between FATP2 and lipid peroxidation markers (Figure 4G). Additionally, a direct association was detected between FATP2 coverage area and lipid 438 439 peroxidation extent (Figure 4H). This data underscores that, contrasting the heightened immune activity in SLC27A2-negative cells, the SLC27A2-positive subset, potentially 440 441 linked to mucociliary clearance anomalies, manifests amplified lipid peroxidation events.

442

443 3.5 Differential transcriptomic characteristics of SLC27A2^{High} CRSwNP

To decipher the transcriptomic distinctions of CRSwNP patients with elevated SLC27A2 444 445 expression, we analyzed the cohort from the GSE136825 study (n = 42, shown in Figure 1), applying a cutoff average value (log_2 FPKM = 4.18) to categorize subjects into 446 'SLC27A2^{Low} CRSwNP' and 'SLC27A2^{High} CRSwNP' groups (Figure 5A). A group of 21 447 healthy individuals provided a baseline for comparison. Profiling of gene expression 448 delineated three distinct transcriptomic clusters, with 2,317 genes exhibiting differential 449 expression among the groups. The 'SLC27A2^{High} CRSwNP' group (Cluster 1) manifested 450 a significant differential expression of 844 genes. A further 661 genes were co-451 upregulated in both the 'SLC27A2^{Low'} and 'SLC27A2^{High'} CRSwNP clusters (Cluster 2), 452 and 812 genes were observed to be downregulated in CRSwNP relative to the healthy 453 454 control group (Cluster 3), as explicated in Figure 5B.

455 Subsequent GO analysis provided insight into the functional characteristics of the 456 identified clusters. Cluster 1 was characterized by genes involved in ciliopathies,

biological oxidation, mucociliary clearance, and arachidonic acid metabolism. The GO 457 terms of Cluster 2 underscored genes linked to the inflammatory response and immune 458 system pathways, emblematic of CRSwNP's inflammatory profile. In stark contrast, 459 Cluster 3 was defined by genes associated with salivary secretion and the regulation of 460 epithelial cell proliferation (Figure 5C). Genes corresponding to pivotal GO terms within 461 each cluster were identified. To corroborate these insights, we cross-validated the gene 462 signatures against an RNA-seg dataset from an independent cohort (GSE179269), 463 detailed in Supplementary Figures 2 and 3. 464

- Notably, Cluster 1, encompassing SLC27A2, included key genes such as ALOX15, 465 which plays a role in inflammation and lipid peroxidation.^{24,26-31} as well as DUOX1 and 466 POR, essential for lipid peroxidation and the escalation of ROS.^{57,58} This cluster also 467 468 contained CCL15, IL5RA, and NOS2, which are associated with airway inflammatory responses,⁵⁹⁻⁶², alongside FOXJ1 and TP73, identified as markers for atypical ciliary 469 morphology and ciliogenesis (Figure 5D and S5A).⁶³ Conversely, the signature genes of 470 Cluster 2 included CCL24, IL4R, and POSTN (Figure S5B), whereas Cluster 3 was 471 472 characterized by the expression of GJC3, LYZ, and STATH (Figure S5C). These findings articulate the distinct transcriptomic signatures of SLC27A2^{High} CRSwNP patients, 473 474 emphasizing the profound roles of lipid peroxidation, ciliopathies, and inflammation in the pathology of the disease, offering a window into the molecular heterogeneity underlying 475 476 CRSwNP.
- 477

478 **3.6 Correlation between increased SLC27A2 expression and CRSwNP severity**

Investigating the correlation between SLC27A2 expression and the severity of CRSwNP. 479 we categorized patients from our cohort (outlined in Table 1) into two groups based on 480 SLC27A2 mRNA expression: 'SLC27A2^{Low} CRSwNP', encompassing 10 patients with 481 lower expression levels, and 'SLC27A2^{High} CRSwNP', including 10 patients with higher 482 expression. Clinical assessments utilizing the Lund-Mackay CT score, Lund-Kennedy 483 endoscopic score, nasal polyp score, and polyp grade consistently demonstrated 484 elevated indices in the 'SLC27A2^{High} CRSwNP' group (Figure 6A). Furthermore, a 485 pronounced correlation emerged between elevated SLC27A2 mRNA expression and 486 increased levels of CRSwNP pathogenesis markers including ALOX15, FOXJ1, and 487

488 *TP73*, primarily in the '*SLC27A2*^{High} CRSwNP' group (Figure 6B and Figure S6A).

Extending our investigation, an in vitro air-liquid interface (ALI) culture model of nasal 489 epithelial cells was employed to discern the effect of SLC27A2 inhibition on disease 490 severity. Nasal epithelial cells derived from four healthy individuals and four CRSwNP 491 patients were subjected to ALI culture. Following treatment with DMSO or 2 µM 492 lipofermata, a SLC27A2/FATP2 inhibitor, we assessed the expression levels of 493 pathogenesis-related markers via RT-gPCR (Figure 6C). Lipofermata treatment resulted 494 in a significant reduction of SLC27A2 expression in both normal and CRSwNP-derived 495 epithelial cells (Figure 6D). Notably, ALOX15 mRNA levels, associated with inflammatory 496 processes, were significantly reduced in CRSwNP cells, while they remained unaffected 497 in cells from healthy controls. Additionally, lipofermata treatment effectively decreased the 498 expression of FOXJ1, a marker of dysregulated ciliogenesis. While the decrease in TP73 499 expression observed did not reach statistical significance (P = 0.057), a trend towards 500 501 downregulation was evident (Figure 6D).

502 These results collectively indicate that elevated *SLC27A2* expression correlates with 503 increased CRSwNP severity, suggesting its utility as a diagnostic biomarker and its 504 potential as a target for therapeutic intervention in severe manifestations of CRSwNP.

505 4. DISCUSSION

CRSwNP is a condition characterized by a complex interplay of inflammatory processes. 506 507 While it has traditionally been associated with eosinophilia and an increased presence of type 2 inflammatory markers, such as IL-4, IL-5, and IgE, recent insights have broadened 508 our understanding of the pathophysiology of CRSwNP. Notably, the disease exhibits a 509 heterogeneous profile, including not only type 2 but also type 1 (IFN-y, IL-12) and type 3 510 (IL-17, IL-22) inflammatory biomarkers. This complexity is further highlighted by the 511 identification of various endotypes, including mixed and unclassifiable forms, which 512 contribute to the diverse clinical manifestations observed in CRSwNP patients.^{9,13} 513 Histological examinations provide additional evidence of this heterogeneity, revealing that 514 up to 40% of CRSwNP patients display a spectrum of infiltrative patterns, encompassing 515 516 neutrophilic, mixed eosinophilic-neutrophilic, and paucigranulocytic types. These findings underscore the multifaceted nature of CRSwNP and the need for tailored therapeutic 517 approaches.^{12,64,65} 518

In this study, we undertook a comprehensive analysis of transcriptomic profiles within 519 520 the cellular landscape of nasal polyp tissue. Utilizing integrated bulk and single-cell RNA sequencing, we discerned a pronounced upregulation of genes associated with lipid 521 522 metabolism in epithelial and myeloid cell populations within the polyp tissue. This finding resonates with the observed higher incidence of CRS in individuals suffering from 523 524 metabolic syndrome, reinforcing the hypothesis of metabolic disturbances playing a role in nasal polyposis.^{22,66-69} The enhanced synthesis of prostaglandin D2 (PGD2) in 525 CRSwNP and its metabolite delta-12-PGD2, implicated in the recruitment and activation 526 of type 2 T helper cells and eosinophils, exemplifies this metabolic dysfunction.⁷⁰ Elevated 527 levels of unsaturated fatty acids and uric acid in distinct CRSwNP subtypes are indicative 528 529 of a metabolic environment that fosters neutrophilic inflammation and a type 2 inflammatory response.^{69,71-73} Furthermore, the observed elevation in glucose levels 530 531 within nasal secretions promotes increased uptake and glycolysis by epithelial cells, accentuating their role in perpetuating inflammation. Our findings articulate the notable 532 533 overexpression of genes driving lipid peroxidation within the nasal polyp epithelium, which may serve to intensify inflammatory processes and compromise the epithelial barrier, 534 thereby elucidating a mechanistic link between lipid oxidation and CRSwNP 535

536 pathophysiology.

FATP2, a member of the long-chain fatty acid (LCFA)-coenzyme A ligase family encoded 537 by SLC27A2, is significantly overexpressed in the NP epithelium of patients with CRSwNP. 538 Such overexpression is implicated in the dysregulation of lipid and fatty acid metabolism, 539 with FATP2 acting as a critical facilitator for the uptake and integration of polyunsaturated 540 fatty acids (PUFAs) into phospholipids, particularly arachidonic acid (AA) and adrenic acid 541 (AdA).⁵⁰ The absence of FATP2 in cells results in reduced levels of arachidonoyl-542 phosphatidylethanolamine (AA-PE). ⁴⁷ This highlights the critical role of FATP2 in 543 synthesizing AA-CoA and AdA-CoA, both essential precursors in the lipid peroxidation 544 pathway.46,47,74 545

Positioned at the nexus of PUFA uptake and conversion, FATP2 operates at the apical 546 547 membrane and endoplasmic reticulum, facilitating the transformation of AA/AdA into their coenzyme A derivatives.²⁹ This process is complemented by ACSL4 and LPCAT3 within 548 549 the ER. promotina the activation and incorporation of AA/AdA-CoA into phosphatidylethanolamine (PE). The subsequent enzymatic action of 15-lipoxygenase. 550 551 encoded by ALOX15, along with the contribution of POR, leads to an accumulation of lipid hydroperoxides, which precipitates an increase in lipid peroxidation and potential 552 cellular injury.^{29,56} Our investigation revealed elevated expression of the enzymes ACSL4, 553 LPCAT3, ALOX15, and POR in SLC27A2-positive epithelial cells of NP, compared to 554 555 SLC27A2-negative cells. Moreover, co-localization of FATP2 with markers of lipid peroxidation was established, exhibiting a positive correlation in stained area percentages. 556 In concordance, GO terms related to lipid peroxidation and the mRNA levels of key 557 enzymes, including ALOX15, DUOX1, and POR, were significantly higher in NP tissue 558 from patients with high SLC27A2 expression. 559

560 While our data suggest a link between FATP2/*SLC27A2* and lipid peroxidation in NP 561 epithelium, the direct contributions of this relationship remain to be fully determined, 562 highlighting an avenue for future research. Notably, the pronounced expression of 563 *SLC27A2* in ciliated cells raises the possibility that the observed loss of these cells in 564 CRSwNP may be attributable to FATP2/*SLC27A2*-mediated lipid peroxidation, presenting 565 an intriguing hypothesis for subsequent exploration.

566 Our analyses reveal a marked expression of genes linked to ciliopathies in SLC27A2-

positive cells and in patients with high SLC27A2 expression in CRSwNP. The aberrant 567 568 expression of these genes is known to contribute to mucociliary dysfunction, which can facilitate the proliferation of pathogenic bacteria and the formation of biofilms, thereby 569 perpetuating a cycle of chronic inflammation. This aligns with prior findings that associate 570 FOXJ1 and TP73 with disrupted ciliary structure and functionality in the epithelium of 571 nasal polyps.⁶³ In our cohort, these markers were notably elevated in the group with high 572 SLC27A2 expression, suggesting a potential mechanistic link between SLC27A2 573 574 overexpression and ciliated cell dysfunction, which may destabilize the epithelial cell environment. 575

576 Clinically significant disparities were observed between the $SLC27A2^{High}$ and 577 $SLC27A2^{Low}$ CRSwNP groups across various disease severity scores, including those 578 derived from Lund-Mackay CT and Lund-Kennedy endoscopic assessments. 579 Therapeutically, the targeted inhibition of SLC27A2/FATP2 using lipofermata attenuated 580 the expression of ALOX15, implicated in inflammation and lipid peroxidation, and FOXJ1, 581 a marker of ciliary disarray, suggesting the modulation of SLC27A2 as a viable treatment 582 strategy.

In conclusion, our study positions SLC27A2 as a pivotal biomarker and a potential target 583 584 for therapeutic intervention in severe CRSwNP. Unbiased transcriptomic profiling has highlighted FATP2/SLC27A2 as a consistently upregulated entity in CRSwNP, 585 586 independent of endotypic categorization and intricately associated with lipid peroxidation processes. Inhibition of SLC27A2 not only resulted in reduced expression of genes 587 central to CRSwNP pathogenesis but also offers a strategic avenue for improving disease 588 prognosis in patients with indeterminate endotypes. These findings advocate for more 589 590 nuanced patient stratification and personalized treatment approaches, particularly in 591 refractory CRSwNP cases.

592 **REFERENCES**

- 593 1. Dietz de Loos D, Lourijsen ES, Wildeman MAM, et al. Prevalence of chronic rhinosinusitis in the 594 general population based on sinus radiology and symptomatology. *J Allergy Clin Immunol.* 595 2019;143(3):1207-1214.
- 596 2. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal 597 Polyps 2020. *Rhinology*. 2020;58(Suppl S29):1-464.
- 598 3. Bachert C, Marple B, Schlosser RJ, et al. Adult chronic rhinosinusitis. *Nat Rev Dis Primers.*599 2020;6(1):86.
- Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis:
 Focus on nasal polyposis. *J Allergy Clin Immunol.* 2015;136(6):1431-1440.
- 5. Zhang Y, Gevaert E, Lou H, et al. Chronic rhinosinusitis in Asia. *J Allergy Clin Immunol.*2017;140(5):1230-1239.
- 6. Wang X, Zhang N, Bo M, et al. Diversity of T(H) cytokine profiles in patients with chronic
 rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. *J Allergy Clin Immunol.*2016;138(5):1344-1353.
- Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Endotypes of chronic
 rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment
 approaches. *Allergy.* 2022;77(3):812-826.
- 8. Wang X, Sima Y, Zhao Y, et al. Endotypes of chronic rhinosinusitis based on inflammatory and
 remodeling factors. *J Allergy Clin Immunol.* 2023;151(2):458-468.
- 612 9. Stevens WW, Peters AT, Tan BK, et al. Associations Between Inflammatory Endotypes and Clinical
 613 Presentations in Chronic Rhinosinusitis. *J Allergy Clin Immunol Pract.* 2019;7(8):2812-2820 e2813.
- 614 10. Poposki JA, Klingler AI, Stevens WW, et al. Elevation of activated neutrophils in chronic
 615 rhinosinusitis with nasal polyps. *J Allergy Clin Immunol.* 2022;149(5):1666-1674.
- Delemarre T, Bochner BS, Simon HU, Bachert C. Rethinking neutrophils and eosinophils in chronic
 rhinosinusitis. *J Allergy Clin Immunol.* 2021;148(2):327-335.
- Delemarre T, Holtappels G, De Ruyck N, et al. A substantial neutrophilic inflammation as regular
 part of severe type 2 chronic rhinosinusitis with nasal polyps. *J Allergy Clin Immunol.*2021;147(1):179-188 e172.
- Ku X, Reitsma S, Wang Y, Fokkens WJ. Highlights in the advances of chronic rhinosinusitis. *Allergy.*2021;76(11):3349-3358.
- 14. Nakayama T, Lee IT, Le W, et al. Inflammatory molecular endotypes of nasal polyps derived from
 Caucasian and Japanese populations. *J Allergy Clin Immunol.* 2021.
- Wang W, Gao Z, Wang H, et al. Transcriptome Analysis Reveals Distinct Gene Expression Profiles
 in Eosinophilic and Noneosinophilic Chronic Rhinosinusitis with Nasal Polyps. *Sci Rep.*2016;6:26604.
- 628 16. Peng Y, Zi XX, Tian TF, et al. Whole-transcriptome sequencing reveals heightened inflammation

629 and defective host defence responses in chronic rhinosinusitis with nasal polyps. Eur Respir J. 630 2019;54(5). 631 17. Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human 632 respiratory epithelial progenitor cells. Nature. 2018;560(7720):649-654. 633 18. Hung LY, Tanaka Y, Herbine K, et al. Cellular context of IL-33 expression dictates impact on anti-634 helminth immunity. Sci Immunol. 2020;5(53). 635 Kotas ME, Moore CM, Gurrola JG, 2nd, et al. IL-13-programmed airway tuft cells produce PGE2, 19. 636 which promotes CFTR-dependent mucociliary function. JCI Insight. 2022;7(13). 637 20. Ma J. Tibbitt CA. Georen SK. et al. Single-cell analysis pinpoints distinct populations of cytotoxic 638 CD4(+) T cells and an IL-10(+)CD109(+) T(H)2 cell population in nasal polyps. Sci Immunol. 639 2021;6(62). 640 Wang W, Xu Y, Wang L, et al. Single-cell profiling identifies mechanisms of inflammatory 21. 641 heterogeneity in chronic rhinosinusitis. Nat Immunol. 2022;23(10):1484-1494. 642 22. Tan S, Zhou S, Fan K, et al. Bulk and single-cell transcriptome sequencing reveal the metabolic 643 feature in chronic rhinosinusitis with polyps. Clin Exp Allergy. 2023. 644 23. Miyata J, Fukunaga K, Kawashima Y, et al. Dysregulated fatty acid metabolism in nasal polyp-645 derived eosinophils from patients with chronic rhinosinusitis. Allergy. 2019;74(6):1113-1124. 646 24. Stevens WW, Staudacher AG, Hulse KE, et al. Activation of the 15-lipoxygenase pathway in aspirin-647 exacerbated respiratory disease. J Allergy Clin Immunol. 2021;147(2):600-612. 648 25. Kohanski MA, Cohen NA, Barrett NA. Epithelial dysregulation in chronic rhinosinusitis with nasal 649 polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD). J Allergy Clin Immunol. 650 2021;148(5):1161-1164. 651 26. Ma XH, Liu JH, Liu CY, et al. ALOX15-launched PUFA-phospholipids peroxidation increases the 652 susceptibility of ferroptosis in ischemia-induced myocardial damage. Signal Transduct Target Ther. 653 2022;7(1):288. 654 27. Hu W, Liang K, Zhu H, Zhao C, Hu H, Yin S. Ferroptosis and Its Role in Chronic Diseases. Cells. 655 2022;11(13). 656 28. Kim R, Hashimoto A, Markosyan N, et al. Ferroptosis of tumour neutrophils causes immune 657 suppression in cancer. Nature. 2022;612(7939):338-346. 658 29.cBayir H, Dixon SJ, Tyurina YY, Kellum JA, Kagan VE. Ferroptotic mechanisms and therapeutic targeting 659 of iron metabolism and lipid peroxidation in the kidney. Nat Rev Nephrol. 2023;19(5):315-336. 660 30. Kristjansson RP, Benonisdottir S, Davidsson OB, et al. A loss-of-function variant in ALOX15 protects 661 against nasal polyps and chronic rhinosinusitis. Nat Genet. 2019;51(2):267-276. 662 Du S, Zeng F, Deng G. Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism 31. 663 for cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):77. 664 32. Mihalj H, Butkovic J, Tokic S, et al. Expression of Oxidative Stress and Inflammation-Related Genes 665 in Nasal Mucosa and Nasal Polyps from Patients with Chronic Rhinosinusitis. Int J Mol Sci.

- Tai J, Shin JM, Park J, Han M, Kim TH. Oxidative Stress and Antioxidants in Chronic Rhinosinusitis
 with Nasal Polyps. *Antioxidants (Basel)*. 2023;12(1).
- Tsai YJ, Hsu YT, Ma MC, Wu CK, Luo SD, Wu WB. Transcriptomic Analysis of Genes Associated
 with Oxidative Stress in Chronic Rhinosinusitis Patients with Nasal Polyps: Identifying Novel Genes
 Involved in Nasal Polyposis. *Antioxidants (Basel)*. 2022;11(10).
- Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: developing guidance for clinical trials. J
 Allergy Clin Immunol. 2006;118(5 Suppl):S17-61.
- van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis
 after sinus surgery in a tertiary referral centre. *Allergy*. 2017;72(2):282-290.
- 676 37. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*.
 677 2013;29(1):15-21.
- 38. Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription
 factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell.*2010;38(4):576-589.
- 39. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
 data with DESeq2. *Genome Biol.* 2014;15(12):550.
- 40. Tripathi S, Pohl MO, Zhou Y, et al. Meta- and Orthogonal Integration of Influenza "OMICs" Data
 Defines a Role for UBR4 in Virus Budding. *Cell Host Microbe.* 2015;18(6):723-735.
- 41. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNAseq data. *BMC Bioinformatics*. 2013;14:7.
- 42. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods.*2012;9(4):357-359.
- 43. Jeon YJ, Jo A, Won J, et al. IL-17C Protects Nasal Epithelium from Pseudomonas aeruginosa
 690 Infection. *Am J Respir Cell Mol Biol.* 2020;62(1):95-103.
- Kim JH, Jang JY, Jang YJ. Human rhinovirus serotypes induces different immune responses. *Virol*J. 2021;18(1):232.
- 45. Yi X, Chang ML, Zhou ZD, et al. LPS induces SGPP2 to participate metabolic reprogramming in
 endothelial cells. *Free Radic Biol Med.* 2023.
- Khan S, Gaivin R, Abramovich C, Boylan M, Calles J, Schelling JR. Fatty acid transport protein-2
 regulates glycemic control and diabetic kidney disease progression. *JCI Insight.* 2020;5(15).
- 47. Veglia F, Tyurin VA, Blasi M, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer.
 698 *Nature*. 2019;569(7754):73-78.
- 48. Vianey-Saban C, Fouilhoux A, Vockley J, Acquaviva-Bourdain C, Guffon N. Improving diagnosis of
 700 mitochondrial fatty-acid oxidation disorders. *Eur J Hum Genet.* 2023;31(3):265-272.
- 49. Nicholas DA, Proctor EA, Agrawal M, et al. Fatty Acid Metabolites Combine with Reduced beta
 Oxidation to Activate Th17 Inflammation in Human Type 2 Diabetes. *Cell Metab.* 2019;30(3):447-

703	461 e445.

- 704 50. Qiu P, Wang H, Zhang M, et al. FATP2-targeted therapies A role beyond fatty liver disease.
 705 *Pharmacol Res.* 2020;161:105228.
- 706 51. Zhang M, Di Martino JS, Bowman RL, et al. Adipocyte-Derived Lipids Mediate Melanoma
 707 Progression via FATP Proteins. *Cancer Discov.* 2018;8(8):1006-1025.
- 52. Larsen SB, Cowley CJ, Sajjath SM, et al. Establishment, maintenance, and recall of inflammatory
 memory. *Cell Stem Cell*. 2021;28(10):1758-1774 e1758.
- Naik S, Larsen SB, Gomez NC, et al. Inflammatory memory sensitizes skin epithelial stem cells to
 tissue damage. *Nature*. 2017;550(7677):475-480.
- 54. Kang K, Park SH, Chen J, et al. Interferon-gamma Represses M2 Gene Expression in Human
 Macrophages by Disassembling Enhancers Bound by the Transcription Factor MAF. *Immunity.*2017;47(2):235-250 e234.
- 55. Divangahi M, Aaby P, Khader SA, et al. Trained immunity, tolerance, priming and differentiation:
 distinct immunological processes. *Nat Immunol.* 2021;22(1):2-6.
- 717 56. Tang D, Kroemer G. Peroxisome: the new player in ferroptosis. *Signal Transduct Target Ther.*718 2020;5(1):273.
- 719 57. Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications.
 720 *Cell Res.* 2021;31(2):107-125.
- 58. Koppula P, Zhuang L, Gan B. Cytochrome P450 reductase (POR) as a ferroptosis fuel. *Protein Cell.*2021;12(9):675-679.
- 59. Du X, Li F, Zhang C, et al. Eosinophil-derived chemokine (hCCL15/23, mCCL6) interacts with CCR1
 to promote eosinophilic airway inflammation. *Signal Transduct Target Ther.* 2021;6(1):91.
- Buchheit KM, Dwyer DF, Ordovas-Montanes J, et al. IL-5Ralpha marks nasal polyp IgG4- and IgEexpressing cells in aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol.*2020;145(6):1574-1584.
- Heredero-Jung DH, Elena-Perez S, Garcia-Sanchez A, et al. Interleukin 5 Receptor Subunit Alpha
 Expression as a Potential Biomarker in Patients with Nasal Polyposis. *Biomedicines*. 2023;11(7).
- 730 62. Zhu M, Gao X, Zhu Z, Hu X, Zhou H, Liu J. The roles of nasal nitric oxide in diagnosis and endotypes
 731 of chronic rhinosinusitis with nasal polyps. *J Otolaryngol Head Neck Surg.* 2020;49(1):68.
- Ki YY, Li CW, Chao SS, et al. Impairment of cilia architecture and ciliogenesis in hyperplastic nasal
 epithelium from nasal polyps. *J Allergy Clin Immunol.* 2014;134(6):1282-1292.
- Succar EF, Li P, Ely KA, Chowdhury NI, Chandra RK, Turner JH. Neutrophils are underrecognized
 contributors to inflammatory burden and quality of life in chronic rhinosinusitis. *Allergy.*2020;75(3):713-716.
- 73765.Tliba O, Panettieri RA, Jr. Paucigranulocytic asthma: Uncoupling of airway obstruction from738inflammation. J Allergy Clin Immunol. 2019;143(4):1287-1294.
- 739 66. Huang GJ, Liu HB. Identification and validation of ferroptosis-related genes for chronic

740		rhinosinusitis with nasal polyps. Eur Arch Otorhinolaryngol. 2023;280(3):1501-1508.
741	67.	Ma Y, Wei Y, Liu X, et al. Metabolomics analysis of metabolic patterns in chronic rhinosinusitis with
742		nasal polyps. <i>Allergy.</i> 2022;77(2):653-656.
743	68.	Chen CL, Ma J, Lu RY, et al. Perturbated glucose metabolism augments epithelial cell
744		proinflammatory function in chronic rhinosinusitis. J Allergy Clin Immunol. 2023;151(4):991-1004
745		e1020.
746	69.	Li JX, Wang ZZ, Zhai GT, et al. Untargeted metabolomic profiling identifies disease-specific and
747		outcome-related signatures in chronic rhinosinusitis. J Allergy Clin Immunol. 2022;150(3):727-735
748		e726.
749	70.	Okano M, Fujiwara T, Yamamoto M, et al. Role of prostaglandin D2 and E2 terminal synthases in
750		chronic rhinosinusitis. Clin Exp Allergy. 2006;36(8):1028-1038.
751	71.	Gazi L, Gyles S, Rose J, et al. Delta12-prostaglandin D2 is a potent and selective CRTH2 receptor
752		agonist and causes activation of human eosinophils and Th2 lymphocytes. Prostaglandins Other
753		<i>Lipid Mediat.</i> 2005;75(1-4):153-167.
754	72.	Jung HJ, Zhang YL, Kim DK, Rhee CS, Kim DY. The Role of NF-kappaB in Chronic Rhinosinusitis
755		With Nasal Polyps. Allergy Asthma Immunol Res. 2019;11(6):806-817.
756	73.	Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H. Soluble Uric Acid Promotes
757		Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. Arterioscler
758		Thromb Vasc Biol. 2020;40(3):570-582.
759	74.	Chen Y, Yan Q, Lv M, et al. Involvement of FATP2-mediated tubular lipid metabolic reprogramming
760		in renal fibrogenesis. Cell Death Dis. 2020;11(11):994.
761		

762

	Control	CRSwNP
RT-qPCR / comparison of severity score	20	20
Age (y), mean ± SD	38.1 ± 52.1	52.1 ± 12.9 [‡]
Male, n (%)	17 (85)	18 (90)
Asthma, n (%)	0	4 (20) [§]
Atopic, n (%)	13 (65)	7 (35)
SNOT-22, mean ± SD	39.5 ± 17.5	42.1 ± 21.4
Lund-Mackay CT score, mean ± SD	0	18.8 ± 4.5
Lund-Kennedy endoscopic score, mean \pm SD	0	9.7 ± 2.9
Nasal polyp score, mean ± SD	0	0.5 ± 2.2
Polyp grade, mean ± SD	0	3.7 ± 1.6
mmunofluorescence staining	3	16
Age (y), mean ± SD	54.3 ± 8.3	53.9 ± 12.5
Male, n (%)	2 (66.7)	14 (87.5)
Asthma, n (%)	0	3 (18.8)
Atopic, n (%)	0	5 (31.3)
SNOT-22, mean ± SD	8.7 ± 6.8	42.3 ± 21.1‡
Lund-Mackay CT score, mean ± SD	0	19.3 ± 4.3 [‡]
Lund-Kennedy endoscopic score, mean ± SD	0	$9.8 \pm 2.8^{\ddagger}$
Nasal polyp score, mean ± SD	0	5.1 ± 2.4‡
Polyp grade, mean ± SD	0	3.8 ± 1.7 [‡]
Dil-red O staining	3	7
Age (y), mean ± SD	61.7 ± 17.2	53.6 ± 20.8
Male, n (%)	1 (33.3)	5 (71.4)
Asthma, n (%)	0	2 (28.6)
Atopic, n (%)	0	4 (57.1)
SNOT-22, mean ± SD	3.7 ± 4.7	38.9 ± 21.9 [‡]
Lund-Mackay CT score, mean ± SD	0	$16.9 \pm 5.3^{\ddagger}$

763 Table 1. Demographics and clinical characteristics of subjects

Lund-Kennedy endoscopic score, mean ± SD	0	9.7 ± 2.4 [‡]
Nasal polyp score, mean ± SD	0	3.7 ± 1.8 [‡]
Polyp grade, mean ± SD	0	$2.7 \pm 0.9^{\ddagger}$
Lipofermata treatment	4	4
Age (y), mean ± SD	37.5 ± 10.3	44.25 ± 12.5
Male, n (%)	3 (75)	4 (100)
Asthma, n (%)	0	0
Atopic, n (%)	2 (50)	0
SNOT-22, mean ± SD	14.8 ± 17.0	47.3 ± 34.4
Lund-Mackay CT score, mean \pm SD	0	$15.5 \pm 4.8^{\ddagger}$
Lund-Kennedy endoscopic score, mean \pm SD	0	$8.8 \pm 4.8^{\ddagger}$
Nasal polyp score, mean ± SD	0	$8.8 \pm 3.2^{\ddagger}$
Polyp grade, mean ± SD	0	3.5 ± 1.9 [‡]

764 ‡ P < 0.05, Mann-Whitney U test

765 §, P < 0.05, chi-square test

766 SNOT, Sino-nasal outcome test

767

768 Table 2. Primers for mRNA expression

Target Gene		sequence (5'-3')
GAPDH	Forward	GACCCCTTCATTGACCTC
	Reverse	GCTAAGCAGTTGGTGGTG
SI C27A2	Forward	TACTCTTGCCTTGCGGACTAA
OLOLINE	Reverse	CCGAAGCAGTTCACCGATATAC
AL OX15	Forward	TGGAAGGACGGGTTAATTCTGA
ALOX IO	Reverse	GCGAAACCTCAAAGTCAACTCT
FOX.I1	Forward	GCCTCCCTACTCGTATGCCA
1 0/101	Reverse	GCCGACAGGGTGATCTTGG
TP73	Forward	CGGGCCATGCCTGTTTACA
	Reverse	TGTCCTTCGTTGAAGTCCCTC

769

770 Figure Legends

771

772 Figure 1. Transcriptomic profiling of the nasal polyp cellular microenvironment

(A) Schematic representation of the transcriptome profiling approach incorporating 773 dataset GSE136825, comparing IT tissues from healthy controls (n = 28) to NP tissues 774 from CRSwNP patients (n = 42). Dataset HRA000772 differentiates NP tissues of 775 nECRSwNP patients (n = 5) from those with ECRSwNP (n = 6). Diagrams were produced 776 777 using BioRender (https://biorender.com/). (B) Heatmap displaying the expression patterns of cell-type specific gene sets among upregulated DEGs in nasal polyp tissues, 778 with values represented as z-scores (left). Gene ontology (GO) annotations for the marker 779 gene sets associated with each distinct cell type are shown on the right. (C) Heatmap 780 781 illustrating the enriched GO terms of lipid metabolic process-related genes upregulated in CRSwNP. (D) Module scores for lipid metabolic processes across individual cells are 782 783 visualized on UMAP (left) and in a violin plot (right). Error bars represent mean values ± SEM. P-values in Figure (F) were determined using the Wilcoxon signed-rank test: * P < 784 0.05, ** P < 0.01, *** P < 0.001. 785

786

Figure 2. Enhanced lipid peroxidation in the nasal polyp epithelium of CRSwNP patients

789 (A) Venn diagram depicting the overlap between upregulated lipid metabolic processrelated genes in CRSwNP and those expressed in the epithelial cells of NP. (B) 790 Expression levels of selected genes in CRSwNP relative to healthy controls, based on 791 data from GSE136825. (C) Dot plot illustrating the specific cell types expressing the 792 793 candidate genes. Color intensity represents the ratio of expression level in each cell 794 cluster relative to the highest expression level across all clusters. Dot size correlates with the percentage of cells in each cluster expressing the gene. (D) Representative 795 immunofluorescence staining images of C11-BODIPY (red) co-localized with DAPI (blue) 796 in both healthy (n = 3) and CRSwNP samples (n = 16). (E) Quantification of the 797 798 percentage area stained by C11-BODIPY, analyzed using ImageJ. Error bars represent mean values ± SEM. P-values were derived from an unpaired t-test. * P < 0.05, ** P < 799 0.01. *** P < 0.001. **** P < 0.0001. Scale bars: 50um and 100um. 800

801

802 Figure 3. Enhanced expression of *SLC27A2*/FATP2 in nasal polyp epithelium

(A) Scatter plot showcasing the disparities in gene expression levels of fatty acid 803 transporter-encoding genes between the CRSwNP and healthy groups based on the 804 805 GSE136825 dataset. (B) mRNA expression levels of SLC27A2, quantified via RT-qPCR and normalized to GAPDH mRNA, comparing CRSwNP (n = 20) and healthy samples (n 806 = 20). (C) UMAP projection of previously published single-cell RNA-seg data (Ordovas-807 Montanes, Jose et al., 2018) comprising 16,415 individual cells, with color coding by cell 808 identity. On the left is a UMAP representation of 16,415 cells derived from nasal scrapings 809 (n = 9), categorized by cell type. The right displays a UMAP representation color-coded 810 811 by disease location, covering samples directly scraped from the ethmoid sinus polyp in CRSwNP (7,886 cells, n = 2 CRSwNP-NP), directly scraped from the IT tissue of 812 813 CRSwNP (2,031 cells, n = 4 CRSwNP-IT), and directly scraped from the IT tissue of a healthy control (6,498 cells; n = 3 Healthy-IT). (D) Gene expression distribution of 814 815 SLC27A2 visualized on feature plots. (E) Illustrative IF staining images of SLC27A2/FATP2 (shown in green) combined with DAPI (depicted in blue) for healthy (n 816 817 = 3) and CRSwNP samples (n = 16). (F) Quantitative assessment of the area stained with anti-FATP2 using ImageJ software. (G) A representative IGV genome browser track, 818 highlighting the normalized tag density associated with SLC27A2. Error bars indicate the 819 mean value ± SEM. Significance was determined using an unpaired t-test: * P < 0.05, ** 820 P < 0.01, *** P < 0.001, **** P < 0.0001. Scale bars are set at 50 µm and 100 µm. 821

822

Figure 4. Unique transcriptomic signatures and enhanced lipid peroxidation in 824 SLC27A2-positive nasal polyp epithelial cells

(A) UMAP plot displaying 9,148 epithelial cells from 11 individuals (5 patients with 825 826 nECRSwNP and 6 patients with ECRSwNP) categorized into 7 subsets. (B) UMAP plots depicting SLC27A2- and SLC27A2+ epithelial cells in nasal polyps from 11 patients with 827 828 CRSwNP. SLC27A2 expression is color-indicated (left). Violin plot showing the expression levels of SLC27A2 in SLC27A2- and SLC27A2+ epithelial cells (right). (C) 829 Violin plot illustrating the expression levels of SLC27A2 across 7 epithelial subsets. (D) 830 Dot plots showcasing representative gene expression levels in both SLC27A2- and 831 SLC27A2+ epithelial cells. (E) Heatmap representing the enriched GO terms of 832

differentially expressed genes (DEGs) between SLC27A2- and SLC27A2+ epithelial 833 cells. Values are -log₁₀(*P*-value). (F) Violin plot displaying the expression levels of ACSL4, 834 LPCAT3, ALOX15, and POR in SLC27A2- and SLC27A2+ epithelial cells. (G) 835 Representative immunofluorescence (IF) staining of SLC27A2/FATP2 (green) and C11-836 BODIPY (red) merged with DAPI (blue) in healthy tissue (n = 3) and CRSwNP tissue (n 837 = 16). (H) Scatter plot depicting correlations between the percentage area stained by anti-838 FATP2 and C11-BODIPY. P-values and correlation coefficients (R) were determined using 839 Spearman correlation analysis. Error bars represent mean values ± SEM. P-values were 840 derived from the Wilcoxon signed-rank test. * P < 0.05. ** P < 0.01. *** P < 0.001. Scale 841 bars: 50 µm and 100 µm. 842

843

Figure 5. Transcriptomic features in CRSwNP with high SLC27A2 expression

- (A) Schematic representation of the classification of CRSwNP patients based on 845 SLC27A2 expression levels using data from the GSE136825 dataset. Diagrams were 846 created using BioRender (https://biorender.com/). (B) Heatmap depicting expression 847 848 levels of differentially expressed genes (DEGs) (FDR < 0.05; two-fold difference in expression; average FPKM > 2). This analysis incorporates both hierarchical and k-849 850 means clustering (k = 3) of 2,317 DEGs among the three groups, based on data from GSE136825. (C) Heatmap of enriched Gene Ontology (GO) terms associated with each 851 of the three clusters. Values are represented as $-\log_{10}(P-value)$. (D) Comparative analysis 852 highlighting the expression levels of select genes from Cluster 1, utilizing data from 853 GSE136825. Error bars indicate mean values ± SEM. P-values were calculated using an 854 unpaired t-test and ordinary one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001, **** 855 856 P < 0.0001.
- 857

858 Figure 6. Association of elevated SLC27A2 expression with severe CRSwNP

(A) Comparison of clinical severity indicators (Lund-Mackay CT score, Lund-Kennedy
 endoscopic score, nasal polyp score, and polyp grade) between *SLC27A2^{Low}* CRSwNP
 and SLC27A2^{High} CRSwNP groups. (B) Association of *SLC27A2* expression with
 ALOX15, FOXJ1, and *TP73* expression. Datasets GSE136825 (upper panel) and
 GSE179269 (lower panel) were subjected to Spearman correlation analysis. Correlation

coefficients (R) and associated P-values are presented. (C) Primary hNECs were cultured 864 using an air-liquid interface (ALI) method and subsequently treated with lipofermata for 865 24 hours. RNA extraction was performed on these cells, followed by RT-qPCR analysis. 866 (D) mRNA expression of SLC27A2, ALOX15, FOXJ1, and TP73 in ALI-cultured hNECs 867 derived from MT tissue of Healthy (n = 4) and NP tissue of CRSwNP (n = 4) individuals. 868 Cells were treated with or without 2 µM lipofermata for 24 hours, and mRNA levels were 869 assessed via RT-qPCR, normalized to GAPDH mRNA levels. Error bars represent the 870 mean ± SEM. Statistical significance was determined using unpaired or paired t-tests. * 871 P < 0.05. ** P < 0.01. *** P < 0.001. **** P < 0.0001. 872



Figure 1_Park et al.



Figure 2_Park et al.





Figure 4_Park et al.



Figure 5_Park et al.



Figure 6_Park et al.